← Back to Search

Hormone Therapy

Adjuvant for Prostate Cancer

Phase 2

Waitlist Available

Led By Tamim Niazi, MD

Research Sponsored by McGill University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trialevaluates a drug and radiation therapy combo to help prostate cancer patients after surgery. It looks at the success rate 5 years later.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

to determine the rate of local and distance failure at 5 years

Side effects data

From 2014 Phase 3 trial • 645 Patients • NCT00079001

62%

Fatigue

54%

Myalgia

25%

Creatinine increased

23%

Nausea

20%

Diarrhea

19%

Serum calcium decreased

17%

Anorexia

14%

Serum potassium decreased

14%

Fever

13%

Vomiting

12%

Chills

12%

Rash desquamating

12%

Serum phosphate decreased

Serum magnesium decreased

Pruritus

Bone pain

Back pain

Alkaline phosphatase increased

Blood glucose increased

Erectile dysfunction

Hypersensitivity

Hemoglobin decreased

Osteonecrosis

Insomnia

Urinary retention

Leukocyte count decreased

Myocardial ischemia

Constipation

Serum sodium decreased

Arthralgia

Dyspnea

Renal failure

Disease progression

Infection

Serum albumin decreased

Bladder infection

Laboratory test abnormal

Pneumonia

Ureteric obstruction

Dehydration

Peripheral motor neuropathy

Musculoskeletal disorder

Skin infection

Pain

Muscle weakness

Alanine aminotransferase increased

Cardiac disorder

Abdominal pain

Lower gastrointestinal hemorrhage

Small intestinal obstruction

Sudden death

Urinary tract infection

Fracture

Lymphocyte count decreased

Neutrophil count decreased

Dizziness

Syncope vasovagal

Hemolysis

Cataract

Pain in extremity

Treatment related secondary malignancy

Dysgeusia

Headache

Urinary frequency

Testicular pain

Cough

Hot flashes

Hypertension

Serum magnesium increased

100%

80%

60%

40%

20%

Study treatment Arm

Zoledronic Acid + Androgen Deprivation Therapy

Placebo + Androgen Deprivation Therapy

Trial Design

1Treatment groups

Experimental Treatment

Group I: AdjuvantExperimental Treatment1 Intervention

Adjuvant suppression plus radiation therapy

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor

394 Previous Clinical Trials

998,335 Total Patients Enrolled

1 Trials studying Prostate Cancer

376 Patients Enrolled for Prostate Cancer

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor

55 Previous Clinical Trials

21,114 Total Patients Enrolled

15 Trials studying Prostate Cancer

3,679 Patients Enrolled for Prostate Cancer

AbbottIndustry Sponsor

750 Previous Clinical Trials

478,254 Total Patients Enrolled

7 Trials studying Prostate Cancer

2,619 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any more volunteers being accepted for this medical research?

"According to clinicaltrials.gov, this medical research endeavour is currently in its recruitment phase having been posted on January 1st 2010 and updated as recently as November 30th 2022."

Answered by AI

Is this medical study welcoming individuals under the age of 35 to participate?

"The requirements to be a part of this trial state that participants must fall between 18 and 85 years of age. Additionally, there are 75 related clinical trials for individuals under the legal age and 1962 studies specifically targeting those over 65."

Answered by AI

What is the scope of participants in this trial?

"Affirmative. Clinicaltrials.gov data confirms that this medical research, initially posted on January 1st 2010, is actively recruiting participants. 46 patients need to be enrolled from two different clinical sites."

Answered by AI

Are there any requirements for eligibility in this medical experiment?

"Interested applicants must have adenocarcinoma and be between 18-85 years of age to qualify for this study. Approximately 46 participants are needed overall."

Answered by AI

Has this therapy been sanctioned by the FDA?

"This treatment's safety rating is assessed as 2 since the trial is in Phase 2, implying that there are some data points supporting its security but no evidence of efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

2010. "Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01255891.

All > Prostate